Swiss patients with variegate porphyria have unique mutations.

BACKGROUND Variegate porphyria (VP), also known as South African porphyria, is a low-penetrance, autosomal dominant disorder as the result of a partial deficiency of protoporphyrinogen oxidase (PPOX). Clinically, VP is characterised by photosensitivity and neurovisceral attacks whereby the two symptoms can appear separately or together in patients. VP is little known in Switzerland. In this study, we report a clinical, biochemical and mutational study of eight Swiss VP patients and their families. RESULTS Six of the eight index patients presented with only skin symptoms, and one with only neurological symptoms. Another patient had both skin and neurological symptoms. Faecal porphyrin excretion was elevated in all patients thus enabling diagnosis. Four different mutations including three novel mutations (G11D, 1041-1042 ins T and 1262-1263 ins 22bp) were identified in this cohort. Mutation 1082-1083 ins C, which had been reported in the French VP population, was shared by five apparently unrelated patients of this study. CONCLUSION The novel PPOX gene mutations are apparently unique to the Swiss population. Both clinical and biochemical presentations varied considerably even among those patients who carried an identical mutation, which does not favour the existence of a genotype-phenotype correlation in VP.

[1]  P. Meissner,et al.  An Analysis of 112 Acute Porphyric Attacks in Cape Town, South Africa: Evidence That Acute Intermittent Porphyria and Variegate Porphyria Differ in Susceptibility and Severity , 2005, Medicine.

[2]  P. Meissner,et al.  Plasma fluorescence scanning and fecal porphyrin analysis for the diagnosis of variegate porphyria: precise determination of sensitivity and specificity with detection of protoporphyrinogen oxidase mutations as a reference standard. , 2004, Clinical chemistry.

[3]  T. Ohashi,et al.  Haplotype analysis excludes the functional protoporphyrinogen oxidase promoter polymorphism -1081G>A as a modifying factor in the clinical expression of variegate porphyria. , 2002, Cellular and molecular biology.

[4]  A. Christiano,et al.  A spectrum of novel mutations in the protoporphyrinogen oxidase gene in 13 families with variegate porphyria. , 2001, The Journal of investigative dermatology.

[5]  J. Deybach,et al.  Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation. , 1999, American journal of human genetics.

[6]  H. Inokuchi,et al.  The human protoporphyrinogen oxidase gene (PPOX): organization and location to chromosome 1. , 1995, Genomics.

[7]  H. Inokuchi,et al.  Cloning of a Human cDNA for Protoporphyrinogen Oxidase by Complementation in Vivo of a hemG Mutant of Escherichia coli(*) , 1995, The Journal of Biological Chemistry.

[8]  E. Minder.  Coproporphyrin isomers in acute-intermittent porphyria. , 1993, Scandinavian journal of clinical and laboratory investigation.

[9]  E. Minder,et al.  Prototype application of a robot in the clinical laboratory enabling fully automated quantification of fecal porphyrins. , 1992, Clinical chemistry.

[10]  M. Poh-Fitzpatrick.  A plasma porphyrin fluorescence marker for variegate porphyria. , 1980, Archives of dermatology.

[11]  R. Day,et al.  The clinical and biochemical features of variegate porphyria: an analysis of 300 cases studied at Groote Schuur Hospital, Cape Town. , 1980, The International journal of biochemistry.